News

The biggest concern of the respondents to our State of the Industry survey was misinformation about vaccines on social media.

The company is expanding the reach of Amazon Care and partnering with health systems and senior living companies to support at-home care.

For many people, telehealth is an inviting option. But some insurers are offering health plans that make it the main way by which people receive primary care.

Cost pressures may increase as the Medicare Hospital Insurance Trust Fund runs low, but the reliance on telehealth that the pandemic wrought is likely to continue, especially for mental health services.

Briana Contreras, editor of Managed healthcare Executive, spoke with Dr. Ian Tong, chief medical officer of Included Health in today’s episode. The two discussed telehealth use vs. in person care, and more specifically, the racial and ethnic differences in this use of care. They concluded the conversation with how telehealth use has continued to expose more benefits for all patients and for the industry through examples like improvements in reimbursement policies and in addressing health equity issues.

A large majority of respondents see a future of endemic COVID-19, but the survey also identified some confidence that the current crop of vaccines will protect against new variants.

Leo Pharma's Adbry (tralokinumab-ldrm) is the second, FDA-approved biologic for atopic dermatitis. Dupixent (dupilumab) was the first.

CMS has proposed covering the anti-amyloid treatment only if the person taking it is enrolled in a clinical trial.

Results of our survey show some tempering of expectation for addressing healthcare disparities and what can be accomplished this year.

But the future of value-based care in oncology is uncertain with no certain successor to the Oncology Care Model in sight.

Remote care technology and drug price limits garnered the most votes for having the biggest effect on the cost and delivery of U.S. healthcare.

Smaller doses are recommended for people with moderate renal impairment and the treatment should not be taken by people with serious kidney disease. There are also drug interactions to be aware of because Paxlovid is an inhibitor of CYP3A.

As the need for rapid tests increase, the nation's largest non-profit patient safety organization evaluated seven COVID-19 rapid tests and found serious gaps in their usability. Results shared that none of the tests were rated as excellent and some had noteworthy usability concerns.

Most of the respondents to our question about optimism of notable improvements in healthcare were in the mild middle.

Lecanemab and donanemab, monoclonal antibodies for Alzheimer’s, are on the list of drugs in late-stage development that Clarivate analysts will have annual sales of a $1 billion or more in the next five years.

Hospital leaders who have historically viewed price transparency as potentially disastrous can tap into these three tips to leave that mindset behind and capitalize on the opportunities that price transparency provides.

In this interview, Briana Contreras, associate editor of Managed Healthcare Executive, spoke with Shara Cohen, CEO of Carallel, an organization built to support caregivers. Cohen not only spoke about who caregivers are and the vital role they play in healthcare, but the challenges they face. She also discussed ways health plans can do better to meet the needs of today’s caregivers.

Hospitals in trouble, Moderna booster = 62.5% effectiveness, Supremes hear mandate arguments, get-used-it strategies the new COVID-19 normal, CDC soft pedals testing, and FDA OKs young teen booster

This year’s State of the Industry focused on the year ahead.

The FDA approved Apretude (cabotegravir extended-release injectable suspension) for pre-exposure prophylaxis (PrEP) for HIV in December. Administered as an injection every other month, Apretude gives people at risk of contracting HIV a PrEP alternative to taking daily pills.

For many provider organizations, one way to address burnout begins with making clinicians’ lives easier by giving them the right technology to seamlessly access critical patient data at the point of care.

The cost-effectiveness group say Lilly’s diabetes treatment should have an annual price of between $5,500 and $5,700. The FDA is expected to make a decision on whether to approve tirzepatide this year.

2021 was a year in which investigators, government officials and drug companies overcame immense challenges to develop successful vaccines against COVID-19. That spirit of innovation is expected to carry over into this year.

There is a great deal of speculation, and apprehension, in the healthcare industry about the 21st Century Cures Act and what it will mean for EHRs and the clinicians who use them.

Leqvio (inclisiran) is the first small interfering RNA therapy approved to lower LDL cholesterol in certain adults at risk for life-threatening cardiovascular events.

But Paxlovid and molnupiravir will be available only at certain Walmart and Sam’s Club locations.

U.S. healthcare is the most expensive healthcare in the world. Many of the policies and programs designed to rein in those costs have been predicated on the idea that information about quality and price would make Americans more discerning shoppers of healthcare — and with that shopping would come some market discipline.

The country is becoming more diverse. Health plans need to adapt by making their provider networks as diverse as possible and committing to diversity in their management ranks.

CMS has started to experiment with a value-based version of Medicare Advantage that allows plans to tweak their offerings in various ways to see whether they might improve outcomes.